Spago Nanomedical AB (publ) (OM: SPAGO)
Health Care · Biotechnology · SE
Skr0.11
-3.49% today · -57.7% 1Y
Spago Nanomedical AB (publ) (OM: SPAGO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.00M and employs 5 people.
Over the last twelve months the share price has lost 57.7%, trading between 0.08 and 0.37.
Tweenvest scores Spago Nanomedical AB (publ) across four factors: quality 26/100, value 60/100, growth 0/100. Its strongest factor is value.
SPAGO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.00M
- Revenue (TTM)
- $392.90K
- P/E
- —
- EPS
- -0.06
- Dividend yield
- —
- Beta (5Y)
- 1.30
- 52-week high
- Skr0.37
- 52-week low
- Skr0.08
- Avg volume (3M)
- —
- Shares outstanding
- 661.57M
- Employees
- 5
- Next earnings
- —
About Spago Nanomedical AB (publ)
Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.
- ISIN
- SE0004899474
- Founded
- 1999
- Listed since
- Jan 16, 2013
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.